The association between the ERBB4 −815A/T polymorphism and clinical outcome serves the hypothesis that ErbB4-targeted therapy could be beneficial for a subgroup of breast cancer patients in the adjuvant setting. This evidence concerns the gene ERBB4 and breast carcinoma.